What technology and detection system does the iLite® CD20 (+) Svar Luc Assay Ready Cells use?

This assay utilizes Cell-based reporter gene assay technology, with a Luminescence detection system.

What is the regulatory status of iLite® CD20 (+) Svar Luc Assay Ready Cells?

The regulatory status is Research Use Only.

About

About Svar

Career

Distributors

Events

Complement Excellence Award

News

Products

All Products

Complement Assays

Cell-Based Assays

Gene Therapy Assays

CCP Assays

Services

CRO Services

Diagnostic Services

Custom Cell Development

Cell Manufacturing

Applications

Potency Testing

Safety Assessment

Biomarker Profiling

Clinical Assessment

Bioanalysis

Regulatory Testing

Complement System Evaluation

Gene & Cell Therapy Evaluation

Biosimilar & Biobetter Assessment

iLite^® CD20 (+) Svar Luc Assay Ready Cells

BM5028

iLite^® CD20 (+) Svar Luc Assay Ready Cells were designed for sensitive and reproducible studies of complement-dependent cytotoxicity (CDC). They enable robust assessment of CDC activity, antibody screening, and functional inhibition using luciferase-based readout.

"Assay-ready" format for rapid and convenient use
Reproducible and safe
A true measure of cell lysis
Reduced assay variability and higher reproducibility compared to cells in culture

Add to quote

Product Overview

The iLite^® CD20 (+) Svar Luc Assay Ready Cells are used for studies of complement-dependent cytotoxicity in test samples, including human serum, to investigate the activity of complement-dependent cytotoxicity in different samples. The cells can also be used to assess the efficiency and screening of antibodies of interest in the development of therapeutic antibodies. Moreover, cells can be utilized to quantify the inhibition of complement-dependent cytotoxicity activity.

iLite^® CD20 (+) Svar Luc Assay Ready Cells are human B lymphocyte Ramos cells (ATCC #CRL-1596) that have been genetically engineered to express Svar luciferase constitutively.

FOR RESEARCH USE ONLY

How it works

Principle of the CDC bioassay

Our CDC cell lines express Svar luciferase from a constitutive promoter. In addition, they overexpress antigens on the cell surface that can be bound by a therapeutic drug antibody.